Sitomet ER Tablet 50 mg + 500 mg combines Sitagliptin and Metformin Hydrochloride in an extended-release (ER) formulation for the effective management of type 2 diabetes mellitus. Sitagliptin, a DPP-4 inhibitor, enhances glucose-dependent insulin secretion and reduces glucagon levels, while Metformin improves insulin sensitivity and decreases hepatic glucose production.

The extended-release form allows once-daily dosing, improves patient compliance, and reduces gastrointestinal side effects commonly associated with conventional Metformin tablets. Sitomet ER is suitable for patients whose blood sugar is not adequately controlled with diet, exercise, or monotherapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Sitagliptin 50 mg
• Metformin Hydrochloride 500 mg (extended-release)

Mechanism of Action

Sitagliptin:

• Inhibits the DPP-4 enzyme, increasing levels of incretin hormones (GLP-1 and GIP)
• Enhances postprandial insulin secretion and suppresses glucagon release

Metformin ER:

• Reduces hepatic glucose production
• Improves peripheral insulin sensitivity
• Delays intestinal absorption of glucose, contributing to more stable blood sugar levels

The combination provides a complementary dual action to achieve better glycemic control while minimizing side effects.

Indications

Sitomet ER Tablet is indicated for:

• Adults with type 2 diabetes mellitus inadequately controlled with diet and exercise
• Patients requiring dual therapy to manage fasting and postprandial glucose levels
• Combination therapy for long-term management and reduction of diabetes-related complications

Dosage & Administration

• Recommended dose: 1 tablet once daily with the main meal of the day
• Swallow the tablet whole; do not crush or chew
• Take with food to reduce gastrointestinal discomfort
• Dose adjustment may be required in patients with renal or hepatic impairment
• Regular monitoring of blood glucose, HbA1c, and kidney function is advised
• Maintain diet and exercise as recommended by the physician

Benefits

• Extended-release formulation allows once-daily dosing for convenience
• Dual-action therapy addresses both insulin secretion and insulin resistance
• Effective control of fasting and postprandial blood sugar
• Reduced gastrointestinal side effects compared to standard Metformin
• Supports long-term glycemic management and reduces diabetes complications

Possible Side Effects

Common side effects:

• Mild gastrointestinal issues (nausea, diarrhea, abdominal discomfort)
• Headache
• Dizziness

Rare but serious side effects:

• Lactic acidosis (associated with Metformin, especially in renal impairment)
• Allergic reactions (rash, swelling, itching)
• Hypoglycemia (rare when used alone, higher risk with other antidiabetic drugs)

Precautions & Warnings

• Avoid in patients with severe renal or hepatic impairment
• Not recommended for type 1 diabetes or diabetic ketoacidosis
• Monitor kidney function regularly due to Metformin content
• Use caution during acute illness, dehydration, or excessive alcohol consumption
• Discontinue immediately if signs of lactic acidosis appear
• Inform your doctor about all other medications being taken

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage

• Store at 20–25°C in a dry, cool place
• Keep in original packaging until use
• Protect from heat, moisture, and direct sunlight
• Keep out of reach of children

Conclusion

Sitomet ER Tablet 50 mg + 500 mg (Sitagliptin + Metformin Hydrochloride) provides effective once-daily dual-action therapy for type 2 diabetes mellitus. By combining enhanced insulin secretion with improved insulin sensitivity, it ensures stable blood sugar control, minimizes side effects, and supports long-term diabetes management.